COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge
Latest Information Update: 29 Jan 2024
Price :
$35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Arterial thrombosis; Deep vein thrombosis; Ischaemia; Myocardial infarction; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTIV 4c
- 12 Dec 2023 Results determining whether anticoagulation had a variable impact on the individual domains measured by EQ-5D-5L, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 23 Mar 2023 Status has been changed to discontinued, as per Results published in the Annals of Internal Medicine
- 12 Mar 2023 Results published in the Annals of Internal Medicine